Wall Street Puts the Peptide Market at $80 Billion
A Citigroup survey says 28% of respondents used a peptide at $90 a month, scaling to $80B a year. What that number counts — and what it leaves out.
Brand launches, primer pieces, broader coverage.
New articles delivered to your inbox every morning. Free.
A Citigroup survey says 28% of respondents used a peptide at $90 a month, scaling to $80B a year. What that number counts — and what it leaves out.
Montana now licenses clinics to sell drugs that cleared only Phase 1. We ran the registry on the six peptides the FDA panel backed. None clears the bar.
A data firm screened 15 million medical records and found 1,039 documented BPC-157 users. Use rose 33-fold since 2020 — and the typical user changed.
A 99% pure peptide can still be risky — the other 1% is the question. What identity and related-substances testing reveal that a purity figure hides.
A US university registered a randomized, placebo-controlled BPC-157 trial in shoulder surgery — 90 days of daily injections. What the protocol tests.
UCLA orthopedists screened 565 studies on BPC-157, TB-500, GHK-Cu and three more. What the scoping review found — and the limit on its scope.
CBP seized 5,000 peptide shipments, de minimis is dead, and an Oct 22 rule strips FDA-regulated mail of the fast lane. The overseas-vs-domestic math.
We ran whois on 10 peptide vendor domains. Two imitation sites are dead at the registry, one resolves to something else entirely. Here's how to check.
A Nature study started semaglutide in 20-month-old mice. Median lifespan rose about 12% and beat calorie restriction on memory. What it does not show.
Structure's ACCG-2671 cut 3.3% body weight from one 10 mg dose with a 6-day half-life. What the first oral amylin data means for peptide buyers.
Semaglutide users logged ~40% fewer asthma attacks and 20% fewer COPD flare-ups across four UK cohorts. What the ERS data supports — and what it doesn't.
TrumpRx lists semaglutide at $199 and tirzepatide at $299. Both are starter doses — maintenance runs $349 to $449. The full cash-price map.
A federal class action says compounded oral tirzepatide tablets have no absorption pathway. What the filing alleges, and the delivery route with real data.
A September 3 genetic study ties GLP-1 receptor activity to male-pattern hair loss — a different mechanism than the shedding seen in July's BMJ cohort.
Somatropin is prescription rHGH — no peptide vendor sells it. Here's how it really differs from the GH-axis secretagogues people search for instead.
A meta-analysis of 680 men found GLP-1s raise total testosterone. Two 2026 reviews report desire falling anyway. The SHBG gap, and the 5-HT2C model.
ESC just gave semaglutide and tirzepatide a Class IIa nod in heart failure with obesity, LVEF 45%+. The exact wording, the trials, and what it changes.
16,242 IBD patients on GLP-1s show 54% lower surgery odds. The one study designed to strip out confounding found nothing. Both datasets, unpacked.